Prevalence of Dyschromatopsia in Glaucoma Patients

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01994564

Enrollment

Registered

2013-11-26

Start date

2012-11-30

Completion date

2014-01-31

Last updated

2013-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open Angle Glaucoma

Keywords

OAG

Brief summary

Glaucoma is a progressive disease resulting in loss of retinal nerve cells and their axons (retinal nerve fibers). Retinal nerve fibers are ordered in a special manner when they enter the optic nerve. Hence, damage to the retinal nerve fibers by glaucoma results in visual field defects at certain locations. Furthermore, the retinal nerve fiber layers from different receptors for different colors are ordered in a special manner as well. Thus, it is possible that glaucomatous damage causes color vision dysfunction (dyschromatopsia). At the moment there is disagreement whether dyschromatopsia occurs at early- to mid-stage or only in end-stage glaucoma. By testing color vision in glaucoma patients the prevalence of dyschromatopsia in glaucoma and in different stages of the disease will be investigated.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diagnosis of open angle glaucoma * visual acuity \>/= 20/50 * age \>/= 18 (no upper limit) * male or female gender

Exclusion criteria

* other type of glaucoma * age \<18 * other retinal disease (e.g. age related macular degeneration) * other disease affecting the optic nerve or the retinal nerve fibers * known color blindness

Design outcomes

Primary

Measure	Time frame	Description
Result from Ishihara Test	Visit 1	Color vision will be tested once by Ishihara plates. Both eyes will be tested separately.

Secondary

Measure	Time frame	Description
Glaucoma stage	Visit 1	Visual field will be tested with 30-2 Humphrey visual field full threshold test. Visual field defects will we graded following the Hodapp-Anderson-Parrish Scale (Hodapp E, Parrish RK, Anderson DR. Classification of Defects in Clinical Decisions in Glaucoma. St. Louis: Mosby, 1993:52-61).

Countries

United States

Outcome results